PT2167492E - Novel amide derivative for inhibiting the growth of cancer cells - Google Patents
Novel amide derivative for inhibiting the growth of cancer cells Download PDFInfo
- Publication number
- PT2167492E PT2167492E PT87661245T PT08766124T PT2167492E PT 2167492 E PT2167492 E PT 2167492E PT 87661245 T PT87661245 T PT 87661245T PT 08766124 T PT08766124 T PT 08766124T PT 2167492 E PT2167492 E PT 2167492E
- Authority
- PT
- Portugal
- Prior art keywords
- inhibiting
- growth
- cancer cells
- amide derivative
- novel amide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20070054997 | 2007-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2167492E true PT2167492E (en) | 2016-02-04 |
Family
ID=40094307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT87661245T PT2167492E (en) | 2007-06-05 | 2008-06-05 | Novel amide derivative for inhibiting the growth of cancer cells |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8188102B2 (en) |
| EP (1) | EP2167492B1 (en) |
| JP (1) | JP5155391B2 (en) |
| KR (1) | KR101013319B1 (en) |
| CN (1) | CN101679384B (en) |
| AR (2) | AR066876A1 (en) |
| AU (1) | AU2008260772B2 (en) |
| BR (1) | BRPI0811069B1 (en) |
| CA (1) | CA2687180C (en) |
| DK (1) | DK2167492T3 (en) |
| ES (1) | ES2558623T3 (en) |
| HK (1) | HK1142591A1 (en) |
| HR (1) | HRP20160007T1 (en) |
| HU (1) | HUE028243T2 (en) |
| IL (1) | IL202154A (en) |
| MX (1) | MX2009012772A (en) |
| MY (1) | MY144972A (en) |
| NZ (1) | NZ582412A (en) |
| PL (1) | PL2167492T3 (en) |
| PT (1) | PT2167492E (en) |
| RU (1) | RU2434010C2 (en) |
| TW (1) | TWI377944B (en) |
| UA (1) | UA96045C2 (en) |
| WO (1) | WO2008150118A2 (en) |
| ZA (1) | ZA201000022B (en) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| US8604044B2 (en) | 2006-09-11 | 2013-12-10 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| US8119616B2 (en) | 2007-09-10 | 2012-02-21 | Curis, Inc. | Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety |
| ES2659725T3 (en) | 2009-05-05 | 2018-03-19 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and disorder treatment procedure |
| KR101217526B1 (en) * | 2010-06-11 | 2013-01-02 | 한미사이언스 주식회사 | Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof |
| US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| KR101317809B1 (en) * | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cell and non-metalic salt lubricant |
| KR101272613B1 (en) * | 2011-10-05 | 2013-06-10 | 한미사이언스 주식회사 | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxy quinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one hydrochloride and intermediates used therein |
| US9586965B2 (en) | 2012-01-13 | 2017-03-07 | Acea Biosciences Inc. | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases |
| US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
| EP2802568A1 (en) | 2012-01-13 | 2014-11-19 | Acea Biosciences, Inc. | Heterocyclic compounds and uses as anticancer agents. |
| US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
| ME02648B (en) | 2012-01-17 | 2017-06-20 | Astellas Pharma Inc | Pyrazine carboxamide compound |
| CN102659764A (en) * | 2012-04-16 | 2012-09-12 | 中国科学院广州生物医药与健康研究院 | Tyrosine kinase inreversible inhibitor, its preparation method and application |
| KR20140096571A (en) * | 2013-01-28 | 2014-08-06 | 한미약품 주식회사 | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one |
| JP6564771B2 (en) | 2013-07-11 | 2019-08-21 | エイシア バイオサイエンシーズ インコーポレイテッド | Pyrimidine derivatives as kinase inhibitors |
| CN104513229A (en) * | 2013-09-28 | 2015-04-15 | 正大天晴药业集团股份有限公司 | Quinazoline derivatives and preparation method thereof |
| CN106068262B (en) * | 2014-04-11 | 2019-10-29 | 海思科医药集团股份有限公司 | Quinazoline derivant and preparation method thereof and application in medicine |
| CN114224894A (en) * | 2014-12-03 | 2022-03-25 | 奥克兰联合服务有限公司 | Kinase inhibitor prodrugs for the treatment of cancer |
| EP3272746B1 (en) * | 2015-03-20 | 2019-12-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Salts of quinazoline derivative and method for preparing same |
| CN107949388B (en) | 2015-10-09 | 2021-10-26 | 艾森医药公司 | Pharmaceutical salts, physical forms and compositions of pyrrolopyrimidine kinase inhibitors and methods of making the same |
| CN109476634B (en) * | 2016-08-25 | 2021-04-02 | 正大天晴药业集团股份有限公司 | Crystal of salt of quinazoline derivative |
| CN108069946B (en) * | 2016-11-08 | 2020-06-05 | 威尚（上海）生物医药有限公司 | Substituted quinazoline compounds having the ability to cross the blood brain barrier |
| CN110167928A (en) * | 2016-12-22 | 2019-08-23 | 勃林格殷格翰国际有限公司 | The quinazoline and derivative that Novel warp benzylamino as SOS1 inhibitor replaces |
| TWI808958B (en) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | Combination therapy involving diaryl macrocyclic compounds |
| EP3590929B1 (en) | 2017-02-28 | 2021-09-15 | Medshine Discovery Inc. | Spiro compound and use thereof |
| CA3059072A1 (en) | 2017-04-07 | 2018-10-11 | ACEA Therapeutics, Inc. | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
| CA3059283A1 (en) * | 2017-04-27 | 2018-11-01 | Astrazeneca Ab | C5-anilinoquinazoline compounds and their use in treating cancer |
| AR113451A1 (en) * | 2017-10-18 | 2020-05-06 | Spectrum Pharmaceuticals Inc | INHIBITORS OF TYROSINE KINASES FROM THE FAMILY OF EGFR MUTANTS |
| EP3733663B1 (en) | 2017-12-19 | 2023-05-17 | Chengdu Jinrui Foundation Biotech Co., Ltd. | 1-[6-[[4-(phenylamino)-6-quinazolinyl]oxy]-3-azabicyclo[3.1.1]hept-3-yl]-2-propen-1-one derivatives and related compounds as irreversible inhibitors of pan-her tyrosine kinase for the treatment of cancer |
| HUE062076T2 (en) | 2017-12-21 | 2023-09-28 | Boehringer Ingelheim Int | Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors |
| RU2020134932A (en) * | 2018-03-27 | 2022-04-27 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | COMPOUNDS WITH ANTITUMOR ACTIVITY AGAINST CANCER CELLS CARRYING MUTATIONS IN THE 19HER2 EXON |
| WO2019223671A1 (en) * | 2018-05-24 | 2019-11-28 | 深圳市塔吉瑞生物医药有限公司 | Substituted aminoquinazoline compound, and pharmaceutical composition and use thereof |
| WO2019233459A1 (en) * | 2018-06-08 | 2019-12-12 | 江苏威凯尔医药科技有限公司 | Human epidermal growth factor receptor inhibitor, preparation method therefor and use thereof |
| CN110577514B (en) * | 2018-06-08 | 2022-07-05 | 江苏威凯尔医药科技有限公司 | Human epidermal growth factor receptor inhibitor and preparation method and application thereof |
| CN108623490A (en) * | 2018-06-22 | 2018-10-09 | 苏州市贝克生物科技有限公司 | The synthetic method of (2Z) -4- (dimethylamino) -2- butenoate hydrochlorates |
| KR20210024568A (en) | 2018-06-25 | 2021-03-05 | 스펙트럼 파마슈티컬즈 인크 | Combination of Pogiotinib with Cytotoxic and/or Targeted Substances with Other Molecules and Uses thereof |
| TW202012391A (en) | 2018-07-04 | 2020-04-01 | 日商第一三共股份有限公司 | Biaryl ether type quinazoline derivatives |
| US11883402B2 (en) * | 2018-09-14 | 2024-01-30 | Hanmi Pharmaceutical Co., Ltd. | Crystalline forms of a quinazoline compound and its hydrochloride salts |
| US20210353627A1 (en) * | 2018-09-21 | 2021-11-18 | Spectrum Pharmaceuticals, Inc. | Novel quinazoline egfr inhibitors |
| WO2020068867A1 (en) | 2018-09-25 | 2020-04-02 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use |
| KR101950942B1 (en) * | 2019-01-28 | 2019-02-22 | 한미약품 주식회사 | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one |
| NZ781366A (en) | 2019-03-19 | 2022-08-26 | Voronoi Inc | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| WO2020219904A1 (en) * | 2019-04-25 | 2020-10-29 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of tyrosine kinase |
| CN114144514A (en) | 2019-05-09 | 2022-03-04 | 富士胶片细胞动力公司 | Method for producing hepatocytes |
| CN114144418B (en) * | 2019-06-19 | 2023-10-10 | 成都金瑞基业生物科技有限公司 | Crystal form and salt form of quinazoline compound and preparation method thereof |
| WO2020262998A1 (en) * | 2019-06-26 | 2020-12-30 | 한미약품 주식회사 | Novel quinazoline derivative having anti-tumor activity and pharmaceutical composition comprising same |
| KR20210049004A (en) | 2019-10-24 | 2021-05-04 | 한미약품 주식회사 | A pharmaceutical preparation comprising an amide derivative inhibiting the growth of cancer cell and a pharmaceutical product containing the same |
| WO2021127397A1 (en) * | 2019-12-19 | 2021-06-24 | Black Diamond Therapeutics, Inc. | Nitrogen heterocyclic compounds and methods of use |
| CA3166298A1 (en) * | 2020-01-29 | 2021-08-05 | John Heymach | Use of quinazoline-based tyrosine kinase inhibitors for the treatment of cancers with nrg1 fusions |
| WO2021231400A1 (en) * | 2020-05-12 | 2021-11-18 | Accutar Biotechnology, Inc. | Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors |
| CN111763215B (en) * | 2020-07-21 | 2021-05-18 | 成都海博为药业有限公司 | Compound with nitrogen-containing heterocyclic structure and preparation method and application thereof |
| CN115803326B (en) * | 2020-11-23 | 2024-03-26 | 上海和誉生物医药科技有限公司 | EGFR inhibitor, preparation method thereof and application thereof in pharmacy |
| WO2022170043A1 (en) * | 2021-02-05 | 2022-08-11 | Accutar Biotechnology, Inc. | Quinazoline derived compounds as egfr inhibitors and their uses thereof |
| WO2022265950A1 (en) | 2021-06-15 | 2022-12-22 | Genentech, Inc. | Egfr inhibitor and perk activator in combination therapy and their use for treating cancer |
| WO2022266426A1 (en) * | 2021-06-17 | 2022-12-22 | Black Diamond Therapeutics, Inc. | 6-(heterocycloalkyl-oxy)-quinazoline derivatives and uses thereof |
| WO2022266427A1 (en) * | 2021-06-17 | 2022-12-22 | Black Diamond Therapeutics, Inc. | 4-(aryl-methyl-amino)-quinazoline derivatives and uses thereof |
| TW202328105A (en) * | 2021-08-24 | 2023-07-16 | 美商安索治療公司 | Quinazoline compounds for treatment of disease |
| CN115894486B (en) * | 2021-09-30 | 2024-02-09 | 北京赛特明强医药科技有限公司 | Hydrogenated pyridoquinazoline compound, composition and application thereof |
| WO2023128350A1 (en) * | 2021-12-30 | 2023-07-06 | 주식회사 비투에스바이오 | Heteroaryl derivative and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
| PL371188A1 (en) * | 2002-03-30 | 2005-06-13 | Boehringer Ingelheim Pharma Gmbh & Co.Kg | 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors |
| GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
| CA2533345A1 (en) * | 2003-07-29 | 2005-02-10 | Astrazeneca Ab | Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors |
| WO2005026151A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
| GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| US20070043010A1 (en) * | 2003-09-25 | 2007-02-22 | Astrazeneca Uk Limited | Quinazoline derivatives |
| JPWO2005090332A1 (en) | 2004-03-23 | 2008-01-31 | 萬有製薬株式会社 | Substituted quinazoline or pyridopyrimidine derivatives |
| US20100234371A1 (en) * | 2005-08-22 | 2010-09-16 | Frank Himmelsbach | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof |
| WO2007055513A1 (en) * | 2005-11-08 | 2007-05-18 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives as a signal transduction inhibitor and method for the preparation thereof |
-
2008
- 2008-06-04 TW TW097120707A patent/TWI377944B/en active
- 2008-06-05 NZ NZ582412A patent/NZ582412A/en unknown
- 2008-06-05 PL PL08766124T patent/PL2167492T3/en unknown
- 2008-06-05 KR KR1020080052867A patent/KR101013319B1/en active IP Right Grant
- 2008-06-05 AR ARP080102395A patent/AR066876A1/en active IP Right Grant
- 2008-06-05 JP JP2010511117A patent/JP5155391B2/en active Active
- 2008-06-05 BR BRPI0811069-7A patent/BRPI0811069B1/en active IP Right Grant
- 2008-06-05 MY MYPI20094841A patent/MY144972A/en unknown
- 2008-06-05 PT PT87661245T patent/PT2167492E/en unknown
- 2008-06-05 WO PCT/KR2008/003162 patent/WO2008150118A2/en active Application Filing
- 2008-06-05 HU HUE08766124A patent/HUE028243T2/en unknown
- 2008-06-05 CN CN2008800188259A patent/CN101679384B/en active Active
- 2008-06-05 AU AU2008260772A patent/AU2008260772B2/en active Active
- 2008-06-05 RU RU2009149307/04A patent/RU2434010C2/en active
- 2008-06-05 UA UAA200913594A patent/UA96045C2/en unknown
- 2008-06-05 MX MX2009012772A patent/MX2009012772A/en active IP Right Grant
- 2008-06-05 DK DK08766124.5T patent/DK2167492T3/en active
- 2008-06-05 EP EP08766124.5A patent/EP2167492B1/en active Active
- 2008-06-05 CA CA2687180A patent/CA2687180C/en active Active
- 2008-06-05 ES ES08766124.5T patent/ES2558623T3/en active Active
- 2008-06-05 US US12/663,263 patent/US8188102B2/en active Active
-
2009
- 2009-11-16 IL IL202154A patent/IL202154A/en active IP Right Grant
-
2010
- 2010-01-04 ZA ZA2010/00022A patent/ZA201000022B/en unknown
- 2010-09-20 HK HK10108928.8A patent/HK1142591A1/en unknown
-
2016
- 2016-01-05 HR HRP20160007TT patent/HRP20160007T1/en unknown
-
2017
- 2017-10-30 AR ARP170103011A patent/AR110003A2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL202154A0 (en) | Novel amide derivative for inhibiting the growth of cancer cells | |
| IL200596A0 (en) | Tetrahydroisoquinolines as tumour growth inhibitors | |
| HK1143367A1 (en) | Quinazolin-oxime derivatives as hsp90 inhibitors hsp90 - | |
| EP2194817A4 (en) | Arrangement for adjusting the width of the carrier means | |
| EP2172447A4 (en) | Amide compound | |
| IL204970A0 (en) | Amide compound | |
| EP2202223A4 (en) | Heterocyclic compound | |
| HK1151291A1 (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
| GB0702854D0 (en) | Method for the synthesis of sucrose-6-esters | |
| HRP20140047T1 (en) | Cycloptopyl amide derivatives | |
| GB0718255D0 (en) | Nucleobase characterisation | |
| EP2210876A4 (en) | Heterocyclic compound | |
| IL201921A0 (en) | 1,3-dihydroimidazol-2-thione derivative as inhibitors of dopamine-beta-hydroxylase | |
| EP2119702A4 (en) | Amide derivative | |
| HK1137482A1 (en) | Improvement of cell growth | |
| GB0605685D0 (en) | Inhibition of tumour growth | |
| EP2117591A4 (en) | Reducing tumor growth | |
| GB2453005B (en) | Macrocyclic tricothecene compounds for inhibiting the growth of cancer cells | |
| GB2459413B (en) | Methods for the synthesis of perfluoroparacyclophane | |
| EP2134365A4 (en) | Compositions and methods for inhibiting tumor cell growth | |
| IL195092A0 (en) | Crystalline form of (s)-1-phenylethylammonium (r)-diphenyl-methanesulphinyl-acetate | |
| EP2176303A4 (en) | Modification of polyolefins | |
| GB0808076D0 (en) | Cell growth inhibition composition | |
| GB0702818D0 (en) | Growth factor | |
| GB0710032D0 (en) | Growth factor |